"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 1 | 4 |
| 2019 | 6 | 0 | 6 |
| 2020 | 5 | 1 | 6 |
| 2021 | 5 | 0 | 5 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 2 | 1 | 3 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Higher Acceptability of the Monthly Dapivirine Ring Versus Daily Oral Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women in Sub-Saharan Africa in the REACH Trial. J Acquir Immune Defic Syndr. 2025 Dec 15; 100(5):415-424.
-
Measuring Pre-Exposure Prophylaxis (PrEP) Stigma Among Adolescent Girls and Young Women in Western Kenya: Scale Development, Validation, and Associations with PrEP Adherence. AIDS Patient Care STDS. 2025 Aug; 39(8):323-338.
-
Longer-acting preexposure prophylaxis product and delivery preferences among U.S. populations disproportionately affected by HIV: a discrete choice experiment. AIDS. 2025 Aug 01; 39(10):1364-1374.
-
Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2025 Apr 15; 98(5S):e129-e135.
-
A Pilot Study of a Sibling-Based Online Intervention to Increase PrEP Uptake and Willingness Among Latino MSM. AIDS Educ Prev. 2024 Oct; 36(5):299-323.
-
We choose: Adolescent girls and young women's choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe. PLoS One. 2024; 19(8):e0308577.
-
Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial. AIDS Behav. 2024 Sep; 28(9):2990-3000.
-
Breaking down relationship barriers to increase PrEP uptake and adherence among adolescent girls and young women in Kenya: safety and preliminary effectiveness results from a pilot cluster-randomized trial. J Int AIDS Soc. 2023 12; 26(12):e26198.
-
Would the Siblings of Latinx Men Who Have Sex With Men Encourage Their Brothers to Use PrEP? Findings From a Feasibility and Acceptability Study. AIDS Educ Prev. 2023 10; 35(5):390-405.
-
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex. AIDS Care. 2024 01; 36(1):80-86.